Maturitas
Volume 57, Issue 4 , Pages 370-381 , 20 August 2007

The effect of transvaginal estradiol on bone in aged women: A randomised controlled trial

  • Helena S. Salminen

      Affiliations

    • Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden
    • Corresponding Author InformationCorresponding author at: Centre for Family and Community Medicine, Alfred Nobels Allé 12, S-14183 Huddinge, Sweden. Tel.: +46 8 52488735; fax: +46 8 52488706.
    • ,
  • Maria E. Sääf

      Affiliations

    • Department of Endocrinology, Metabolism and Diabetes, Karolinska Hospital and Karolinska Institutet, Stockholm, Sweden
    • ,
  • Sven-Erik Johansson

      Affiliations

    • Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Hans Ringertz

      Affiliations

    • Department of Surgical Sciences, Section for Diagnostic Radiology, Karolinska Institutet, Stockholm, Sweden
    • ,
  • Lars-Erik Strender

      Affiliations

    • Centre for Family and Community Medicine, Karolinska Institutet, Stockholm, Sweden

Received 3 January 2007 ,Revised 19 March 2007 ,Accepted 21 March 2007.

References 

  1. Avenell A, Gillespie WJ, Gillespie LD, O’Connell DL. Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Library 2005; issue 4 [CD000227].
  2. Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial FIT Research Group. J Clin Endocrinol Metab. 2000;85:4118–4124
  3. Bygdeman M, Swahn ML. Replens versus dienoestrol cream in the symptomatic treatment of vaginal atrophy in postmenopausal women. Maturitas. 1996;23:259–263
  4. Cauley JA, Black DM, Barrett-Connor E, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). Am J Med. 2001;110:442–450
  5. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in the elderly women. N Engl J Med. 1992;327:1637–1642
  6. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670–676
  7. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol. 2004;104:443–451
  8. Gluer CC, Blake G, Lu Y, Blunt BA, Jergas M, Genant HK. Accurate assessment of precision errors: how to measure the reproducibility of bone densitometry techniques. Osteoporos Int. 1995;5:262–270
  9. Hayashi T, Ito I, Kano H, Endo H, Iguchi A. Estriol (E3) replacement improves endothelial function and bone mineral density in very elderly women. J Gerontol A Biol Sci Med Sci. 2000;55:B183–190
  10. Heimer GM, Englund DE. Enterohepatic recirculation of oestriol studied in cholecystectomized and non-cholecystectomized menopausal women. Ups J Med Sci. 1984;89:107–115
  11. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605–613
  12. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med. 2006;354:669–683
  13. Johnston A. Estrogens – pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation – Estring. Acta Obstet Gynecol Scand Suppl. 1996;163:16–25
  14. Kullenberg R. Reference database for dual X-ray and laser calscan bone densitometer. J Clin Densitom. 2003;6:367–371
  15. Little RJ, Raghunathan T. On summary measures analysis of the linear mixed effects model for repeated measures when data are not missing completely at random. Stat Med. 1999;18:2465–2478
  16. Looker AC, Wahner HW, Dunn WL, et al. Proximal femur bone mineral levels of US adults. Osteoporos Int. 1995;5:389–409
  17. Lufkin EG, Wahner HW, O’Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1–9
  18. Michaelsson K, Baron JA, Farahmand BY, Ljunghall S. Use of low potency estrogens does not reduce the risk of hip fracture. Bone. 2002;30:613–618
  19. Naessen T, Berglund L, Ulmsten U. Bone loss in elderly women prevented by ultralow doses of parenteral 17 beta-estradiol. Am J Obstet Gynecol. 1997;177:115–119
  20. Naessen T, Rodriguez-Macias K, Lithell H. Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women. J Clin Endocrinol Metab. 2001;86:2757–2762
  21. Povoa G, Roovete A, Hall K. Cross-reaction of serum somatomedin-binding protein in a radioimmunoassay developed for somatomedin-binding protein isolated from human amniotic fluid. Acta Endocrinol (Copenh). 1984;107:563–570
  22. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17 beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. JAMA. 2003;290:1042–1048
  23. Rapuri PB, Gallagher JC, Haynatzki G. Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women. J Clin Endocrinol Metab. 2004;89:4954–4962
  24. Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res. 1998;13:763–773
  25. Rogers A, Saleh G, Hannon RA, Greenfield D, Eastell R. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. J Clin Endocrinol Metab. 2002;87:4470–4475
  26. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321–333
  27. Salminen H, Saaf M, Ringertz H, Strender LE. Bone mineral density measurement in the calcaneus with DXL: comparison with hip and spine measurements in a cross-sectional study of an elderly female population. Osteoporos Int. 2005;16:541–551
  28. Schmidt G, Andersson SB, Nordle O, Johansson CJ, Gunnarsson PO. Release of 17-beta-oestradiol from a vaginal ring in postmenopausal women: pharmacokinetic evaluation. Gynecol Obstet Invest. 1994;38:253–260
  29. Soderberg S, Ahren B, Eliasson M, Dinesen B, Brismar K, Olsson T. Circulating IGF binding protein-1 is inversely associated with leptin in non-obese men and obese postmenopausal women. Eur J Endocrinol. 2001;144:283–290
  30. Stone K, Bauer DC, Black DM, Sklarin P, Ensrud KE, Cummings SR. Hormonal predictors of bone loss in elderly women: a prospective study. The Study of Osteoporotic Fractures Research Group. J Bone Miner Res. 1998;13:1167–1174
  31. Suckling J, Lethaby A, Kennedy R. Localoestrogen for vaginal atrophy in postmenopausal women. Cochrany Library 2005, issue 2.
  32. Weisberg E, Ayton R, Darling G, et al. Endometrial and vaginal effects of low-dose estradiol delivered by vaginal ring or vaginal tablet. Climacteric. 2005;8:83–92
  33. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-h growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab. 1991;72:374–381
  34. WHO . Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Geneva: WHO; 1994;Report 843

PII: S0378-5122(07)00125-9

doi: 10.1016/j.maturitas.2007.03.005

Maturitas
Volume 57, Issue 4 , Pages 370-381 , 20 August 2007

Article Tools

* Image Usage & Resolution